BCDA - Biocardia, Inc.

Insider Purchase by Stertzer Simon H (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Stertzer Simon H, serving as Dir at Biocardia, Inc. (BCDA), purchased 398,400 shares at $1.25 per share, for a total transaction value of $498,000.00. Following this transaction, Stertzer Simon H now holds 714,275 shares of BCDA.

This purchase represents a 126.00% increase in Stertzer Simon H's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, September 19, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, September 23, 2025, 4 days after the trade was made.

Biocardia, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Stertzer Simon H

Stertzer Simon H

Dir

Simon H. Stertzer, M.D. is a pioneering cardiologist and Professor Emeritus of Medicine at Stanford University School of Medicine, Division of Cardiovascular Medicine.[[2]](https://profiles.stanford.edu/simon-stertzer)[[3]](https://www.biocardia.com/about-us/board-of-directors/id/1018) He performed the first percutaneous coronary angioplasty in the United States in 1978, authored over 140 peer-reviewed articles, and co-founded several medical technology companies including Arterial Vascular Engineering (acquired by Medtronic), Quanam Medical, BioCardia (founded 1999), and Avenda Health.[[2]](https://profiles.stanford.edu/simon-stertzer)[[3]](https://www.biocardia.com/about-us/board-of-directors/id/1018)[[6]](https://simonstertzer.com/biocardia-inc/) Dr. Stertzer has served on BioCardia, Inc.'s (BCDA) board since 2002, previously as Chairman (2008-present per some sources), and remains a director.[[2]](https://profiles.stanford.edu/simon-stertzer)[[3]](https://www.biocardia.com/about-us/board-of-directors/id/1018)[[7]](https://simonstertzer.com/insights/) He holds approximately 714,275 shares valued at over $907,129 and has made significant recent purchases, including 398,400 shares for $498,000 on September 19, 2025, and 39,289 shares worth $90,515 in early March 2025.[[1]](https://www.moomoo.com/community/feed/simon-h-stertzer-director-on-september-19-2025-executed-a-115254353920006)[[4]](https://www.gurufocus.com/insider/110199/simon-h-stertzer)[[5]](https://www.waiker.ai/data-lab/waiker-news/3374)[[8]](https://www.tradingview.com/news/tradingview:f4f6b3b60b4bb:0-biocardia-director-simon-h-stertzer-acquires-38-289-shares/)[[9]](https://www.investing.com/news/insider-trading-news/biocardia-director-stertzer-buys-498k-in-shares-93CH-4251366) His education includes an M.D. from New York University (1961), fellowship in Cardiovascular Medicine at NYU (1967), and A.B. from Union College (1957).[[2]](https://profiles.stanford.edu/simon-stertzer)[[3]](https://www.biocardia.com/about-us/board-of-directors/id/1018)

View full insider profile →

Trade Price

$1.25

Quantity

398,400

Total Value

$498,000.00

Shares Owned

714,275

Trade Date

Friday, September 19, 2025

156 days ago

SEC Filing Date

Tuesday, September 23, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Biocardia, Inc.

Company Overview

No company information available
View news mentioning BCDA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/457920

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime